QUINTESSENTIAL-2

1. 01

   An attractive non-BCMA option, with superiority still an open question

2. 02

   Less persistent GPRC5D toxicity does not resolve the non-ICANS neurologic signal

3. 03

   Post-BCMA placement is attractive, but antigen switching is not an automatic rule

4. 04

   Earlier CAR-T is framed as a remission opportunity, not a guaranteed cure

5. 05

   Referral and access remain limiting even when enthusiasm and center capacity improve

6. 06

   Holding and bridging therapy have different purposes and different constraints

7. 07

   CAR-T deferral prompts risk-adapted alternatives, with substantial supportive-care qualifications

8. 08

   Off-the-shelf alternatives depend on eligibility, sequencing and treatment burden

9. 09

   MRD is discussed as an earlier evidence signal and a treatment-stop question—not a stopping rule

An aspect marked incomplete is a question the public commentary did not let us answer. We show it rather than hide it.

Screened window

2024-12-13 → 2026-10-07

Cited window

2024-12-13 → 2026-10-07

Retrieved

2026-10-09

Title

A Phase 3, Randomized, Open-Label, Multicenter Study to Compare the Efficacy and Safety of Arlocabtagene Autoleucel (BMS-986393), a GPRC5D-directed CAR-T Cell Therapy, Versus Standard Regimens in Adult Participants With Relapsed or Refractory and Lenalidomide-exposed Multiple Myeloma

Registry

NCT06615479

Study IDs

CA088-1007

Sponsor

Juno Therapeutics, Inc., a Bristol-Myers Squibb Company

Collaborators

Celgene Corporation

Design

Phase 3 · interventional, randomized, parallel, phase3

Status

Recruiting

Enrollment

440 estimated

Start

2025-03-12 actual

Primary completion

2027-12-30 estimated

Primary endpoint

Progression Free Survival (PFS)

Interventions

7 registered

This report does not judge efficacy, estimate HCP prevalence or consensus or give treatment advice.

• –Sources were found by searching for the trial's name, registry number and known aliases. Discussion that refers to the trial without naming it may be missing.
• –10 points raised by the independent review are not yet resolved in this edition, such as a clinician view not yet captured as evidence or a qualifier to restore. The next refresh takes them up.
• –Out of scope in retained sources: 21 passages in the reviewed sources discuss other trials or topics outside this report's scope; they are not part of this edition.
• –Further source limits: the search also described the trial without its name, to find discussion that does not name it; sources found that way were screened by their titles before any was read; some of those sources were set aside as about other trials.
• –The reviewed material is not a representative sample of HCP opinion. Discussion without the indexed trial name or aliases, including unnamed references or transcription variants, may be absent; the report therefore cannot establish prevalence or consensus.
• –No exact-trial publication or standalone protocol was available in the supplied material, and regulatory context for BMS-986393 was incomplete. This limits independent interpretation of the trial-specific questions raised by speakers.
• –Earlier-study efficacy and safety figures are attributed speaker accounts with differing populations, doses, follow-up or unspecified comparisons. They are not QUINTESSENTIAL-2 results and should not be combined as one estimate.
• –Anonymous panel passages cannot be assigned to nearby named speakers. Moderator summaries and reported prior responses do not establish individual ownership of votes or preferences.
• –Several timing statements are forecasts or publication-relative expectations. The report does not reconcile them into a verified enrollment or readout chronology.

How reports are built and checked: Methods.

Last checked Oct 9, 2026. Versions follow semver: a new or changed finding is a minor version, more evidence without a material change is a patch.

release 7cf6c378989c07c718bc8393e5ed30ab3274a113041e5f3c9e3b9fa60dba4d5b

The same record as JSON or Markdown, or through the Erudio MCP server.

curl https://www.erudio.com/reports/quintessential-2-nct06615479.json
curl https://www.erudio.com/reports/quintessential-2-nct06615479.md

# MCP (https://mcp.erudio.com/mcp)
get_report_card({ "slug": "quintessential-2-06615479" })